US2019328714A1PendingUtilityA1

Mazindol combination in the treatment of attention-deficit/hyperactivity

59
Assignee: NLS 1 PHARMA AGPriority: Apr 11, 2006Filed: Jul 10, 2019Published: Oct 31, 2019
Est. expiryApr 11, 2026(expired)· nominal 20-yr term from priority
Inventors:Eric Konofal
A61P 43/00A61P 25/26A61P 25/20A61P 25/18A61P 25/28A61P 25/16A61P 25/00A61K 31/4188A61K 45/06A61K 31/555A61K 31/4184A61K 31/41A61K 33/26A61K 9/0053
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.

Claims

exact text as granted — not AI-modified
10 - 15 . (canceled) 
     
     
         16 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and mazindol. 
     
     
         17 . The composition of  claim 16 , further comprising iron or a pharmaceutically acceptable salt thereof and/or a psychostimulant.

Join the waitlist — get patent alerts

Track US2019328714A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.